scispace - formally typeset
Journal ArticleDOI

Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

TLDR
Sphingosine 1-phosphate modulators as therapeutic agents in targeting leukocyte trafficking and inflammation in inflammatory bowel disease and the available evidence for efficacy, safety and pharmacokinetics of S1P receptor modulators in IBD and other immune-mediated disorders are summarized.
About
This article is published in Nature Reviews Gastroenterology & Hepatology.The article was published on 2022-02-14. It has received 27 citations till now. The article focuses on the topics: Medicine & Immune system.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine

TL;DR: Of special interest are results from the use of oral sphingosine 1-phosphate (S1P) receptor modulators, based on S1P activities to target lymphocyte recirculation in the mucosa, acting as immunosuppressive agents.
Journal ArticleDOI

Emerging therapies for ulcerative colitis

TL;DR: This review focuses on three drug classes that have recently been approved or are awaiting approval for UC: antibodies against interleukin (IL)-23, sphingosine-1-phosphate receptor (S1PR) modulators, and selective inhibitors of Janus kinases (JAK).
Journal ArticleDOI

Ozanimod: A Review in Ulcerative Colitis

Julia Paik
- 01 Aug 2022 - 
TL;DR: Ozanimod (Zeposia®) as mentioned in this paper is the first S1PR modulator to be approved for the treatment of adults with moderately to severely active ulcerative colitis.
Journal ArticleDOI

Neutrophil CEACAM1 determines susceptibility to NETosis by regulating the S1PR2/S1PR3 axis in liver transplantation

TL;DR: In this paper , the significance of neutrophil CC1 signaling in mouse and human OLT recipients was investigated in the experimental and clinical setting. And they found that neutrophils are the primary proinflammatory sentinel in the ischemia-reperfusion injury (IRI) mechanism in orthotopic liver transplantation (OLT).
Journal ArticleDOI

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs

TL;DR: A meta-analysis of the systems parameters affecting oral drug pharmacokinetics was conducted in this paper , where the information gathered on intestine, liver and blood proteins and other physiological parameters was incorporated into a physiologically based pharmacokinetic (PBPK) platform to create a virtual population of Crohn's disease patients, with a view for guiding dose adjustment in the absence of clinical data in CD.
References
More filters
Journal ArticleDOI

Integrins: Bidirectional, Allosteric Signaling Machines

TL;DR: Current structural and cell biological data suggest models for how integrins transmit signals between their extracellular ligand binding adhesion sites and their cytoplasmic domains, which link to the cytoskeleton and to signal transduction pathways.
Journal ArticleDOI

Chemokines — Chemotactic Cytokines That Mediate Inflammation

TL;DR: This review introduces the burgeoning family of cytokines, with special emphasis on their role in the pathophysiology of disease and their potential as targets for therapy.
Journal ArticleDOI

EASL Recommendations on Treatment of Hepatitis C

TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Journal ArticleDOI

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

TL;DR: It is established that S1P1 is essential for lymphocyte recirculation and that it regulates egress from both thymus and peripheral lymphoid organs.
Journal ArticleDOI

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Related Papers (5)